Biological-E will run a clinical trial of Providence's vaccine in India and seek emergency use approval. (Image for illustration)
India's government said on Thursday it has inked a deal with domestic vaccine maker Biological-E for 300 million COVID-19 vaccine doses for INR15 billion (US$205.62 million), the first such order for unapproved shots.
The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.
Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnson's COVID-19 shot annually, said on Tuesday it entered into a licensing agreement with Providence
Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India.
Biological-E will run a clinical trial of Providence's vaccine in India and seek emergency use approval.
India, world's second most populous country has suffered a disastrous second wave of infections that is only now abating. Health experts India needs to carry out mass vaccination of its 1.3 billion people to reduce the impact of subsequent waves.
- U.S. to Pay $1 Billion for 100 Million Doses of a COVID-19 Vaccine Candidate
- WHO, GAVI seek 190 mln COVID-19 vaccine doses by end-June to fill gap
- Vietnam to buy 30 million doses of COVID-19 vaccine from UK
- Made-in-Vietnam Covid-19 vaccine tested on monkeys
- Phase 3 clinical trial of Vietnamese-made vaccine to be conducted in 2021
- Clinical trial research programme launched for second local COVID-19 vaccine
- Vietnam to test highest dose of Covid-19 vaccine
- COVID-19 vaccine: Vietnam plans human trials at the end of November 2020
- Brazil buys 100 million more doses of Pfizer's COVID-19 vaccine